Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis
- 1 July 2014
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 210 (7) , 419-425
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinomaOncology Reports, 2010
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell FeaturesGastroenterology, 2009
- The Stem Cell Marker CD133 (Prominin-1) Is Expressed in Various Human Glandular EpitheliaJournal of Histochemistry & Cytochemistry, 2008
- Human hepatic stem cells from fetal and postnatal donorsJournal of Experimental Medicine, 2007
- CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicityInternational Journal of Cancer, 2007
- Isolation and Characterization of a Stem Cell Population from Adult Human LiverStem Cells, 2006
- Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cellsBiochemical and Biophysical Research Communications, 2006
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- Extracellular matrix remodeling in hepatocellular carcinoma: Effects of soil on seed?Medical Hypotheses, 2006
- Histopathologic Evaluation of Hepatocellular Carcinoma with Special Reference to Small Early Stage TumorsSeminars in Liver Disease, 1999